GRM5; GRM1; GRM3; GRM2; GRM8; GRM4; | |
ADORA3; | |
TSHR; | |
GLA; TDP1; BLM; CDA; GFER; HSD17B10; ALDH1A1; | |
GRIK3; GRIK5; GRIK1; GRIA4; GRIK2; GRIA2; | |
CA12; CA9; CA7; | |
PPARA; PPARD; | |
CASP1; CASP7; | |
TLR2; | |
NFKB1; | |
SLC1A1; SLC28A1; SLC28A3; | |
LMNA; FABP3; FABP5; FABP2; FABP4; MAPT; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Ionotropic glutamate receptor | GRIK3 | Glutamate receptor ionotropic kainate 3 | Q13003 | CHEMBL3684 |
Ionotropic glutamate receptor | GRIK5 | Glutamate receptor ionotropic kainate 5 | Q16478 | CHEMBL2675 |
Ionotropic glutamate receptor | GRIK1 | Glutamate receptor ionotropic kainate 1 | P39086 | CHEMBL1918 |
Ionotropic glutamate receptor | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | P48058 | CHEMBL3190 |
Ionotropic glutamate receptor | GRIK2 | Glutamate receptor ionotropic kainate 2 | Q13002 | CHEMBL3683 |
Ionotropic glutamate receptor | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | P42262 | CHEMBL4016 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
SLC superfamily of solute carriers | SLC1A1 | Excitatory amino acid transporter 3 | P43005 | CHEMBL2721 |
SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family C GPCR) | GRM5 | Metabotropic glutamate receptor 5 | P41594 | CHEMBL3227 |
Small molecule receptor (family C GPCR) | GRM1 | Metabotropic glutamate receptor 1 | Q13255 | CHEMBL3772 |
Small molecule receptor (family C GPCR) | GRM3 | Metabotropic glutamate receptor 3 | Q14832 | CHEMBL2888 |
Small molecule receptor (family C GPCR) | GRM2 | Metabotropic glutamate receptor 2 | Q14416 | CHEMBL5137 |
Small molecule receptor (family C GPCR) | GRM8 | Metabotropic glutamate receptor 8 | O00222 | CHEMBL3228 |
Small molecule receptor (family C GPCR) | GRM4 | Metabotropic glutamate receptor 4 | Q14833 | CHEMBL2736 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
CC | GO:0044456; synapse part | GO:0042734; presynaptic membrane | 7.640E-13 | 2.377E-09 | GRIK2, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
MF | GO:0005215; transporter activity | GO:0005234; extracellularly glutamate-gated ion channel activity | 1.934E-12 | 4.679E-09 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
BP | GO:0009987; cellular process | GO:0035235; ionotropic glutamate receptor signaling pathway | 1.623E-11 | 3.533E-08 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
MF | GO:0005215; transporter activity | GO:0015277; kainate selective glutamate receptor activity | 9.636E-11 | 1.399E-07 | GRIK1, GRIK2, GRIK3, GRIK5 |
BP | GO:0023052; signaling | GO:0060079; excitatory postsynaptic potential | 7.888E-09 | 5.540E-06 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
MF | Unclassified; | GO:0004872; receptor activity | 8.365E-09 | 5.692E-06 | ADORA3, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, PPARA, PPARD, TLR2, TSHR |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.903E-07 | 8.633E-05 | CYP1A2, CYP2C19, CYP3A4 |
MF | Unclassified; | GO:0099600; transmembrane receptor activity | 2.098E-07 | 8.960E-05 | ADORA3, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, TSHR |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.362E-07 | 9.892E-05 | FABP2, FABP3, FABP4, FABP5 |
CC | GO:0044456; synapse part | GO:0045211; postsynaptic membrane | 3.277E-07 | 1.321E-04 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM3 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.074E-06 | 6.742E-04 | CYP1A2, CYP2C19, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.271E-06 | 1.208E-03 | CA12, CA7, CA9 |
MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 4.616E-06 | 1.272E-03 | SLC28A1, SLC28A3 |
MF | GO:0060089; molecular transducer activity | GO:0001641; group II metabotropic glutamate receptor activity | 4.616E-06 | 1.272E-03 | GRM2, GRM3 |
BP | Unclassified; | GO:0099566; regulation of postsynaptic cytosolic calcium ion concentration | 1.383E-05 | 3.104E-03 | GRM1, GRM5 |
BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.383E-05 | 3.104E-03 | SLC28A1, SLC28A3 |
BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.383E-05 | 3.104E-03 | SLC28A1, SLC28A3 |
MF | GO:0060089; molecular transducer activity | GO:0099583; neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration | 1.383E-05 | 3.104E-03 | GRM1, GRM5 |
CC | GO:0032991; macromolecular complex | GO:0032983; kainate selective glutamate receptor complex | 1.383E-05 | 3.104E-03 | GRIK2, GRIK5 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.762E-05 | 5.782E-03 | CYP1A2, CYP3A4 |
MF | GO:0005215; transporter activity | GO:0004971; AMPA glutamate receptor activity | 2.762E-05 | 5.782E-03 | GRIA2, GRIA4 |
BP | GO:0009987; cellular process | GO:0010646; regulation of cell communication | 2.865E-05 | 5.941E-03 | BLM, CA7, CASP1, GFER, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, LMNA, MAPT, NFKB1, PPARD, TLR2 |
BP | GO:0023052; signaling | GO:0023051; regulation of signaling | 3.412E-05 | 6.879E-03 | BLM, CA7, CASP1, GFER, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, LMNA, MAPT, NFKB1, PPARD, TLR2 |
BP | GO:0050896; response to stimulus | GO:0009719; response to endogenous stimulus | 3.790E-05 | 7.502E-03 | BLM, CA9, CASP7, CYP1A2, FABP3, GRM5, NFKB1, PPARA, TLR2, TSHR |
BP | GO:0009987; cellular process | GO:0007196; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 4.869E-18 | 3.534E-14 | GRIK3, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa04724 | Glutamatergic synapse_Homo sapiens_hsa04724 | 7.362E-20 | 8.025E-18 | GRIA2; GRIK5; SLC1A1; GRIK3; GRIK1; GRIK2; GRM1; GRM3; GRM2; GRM5; GRM4; GRM8; GRIA4 |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.571E-16 | 1.401E-14 | GRIA2; GRIK5; GRIK3; GRIK1; GRIK2; TSHR; GRM1; GRM3; GRM2; GRM5; GRM4; ADORA3; GRM8; GRIA4 |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 6.423E-09 | 2.334E-07 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 5.317E-07 | 1.449E-05 | GRM3; GRM2; GRM5; GRM4; GRM8; GRM1 |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 3.323E-06 | 7.244E-05 | GRM3; GRIA2; GRM2; NFKB1 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 5.300E-06 | 8.933E-05 | CASP7; CASP1; NFKB1; TLR2 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.849E-05 | 6.450E-04 | GRIA2; PPARA; NFKB1; TSHR; GRIA4 |
hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 5.917E-05 | 6.450E-04 | GRIA2; GRM5; GRM1; GRIA4 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.029E-05 | 4.127E-04 | CYP1A2; CYP3A4; CYP2C19 |
hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 3.594E-04 | 3.265E-03 | GRIA2; GRM5; GRM1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.436E-04 | 3.265E-03 | CYP1A2; ALDH1A1; CYP3A4 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 4.097E-04 | 3.435E-03 | CYP1A2; CYP3A4; CYP2C19 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.737E-06 | 8.933E-05 | CA12; CA7; CA9 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 5.234E-04 | 4.075E-03 | CASP7; CASP1; NFKB1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.795E-04 | 4.938E-03 | CYP1A2; CYP3A4; CYP2C19 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.156E-03 | 2.047E-02 | CASP7; LMNA; NFKB1 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 3.904E-03 | 2.364E-02 | CASP7; PPARA; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 5.256E-03 | 2.728E-02 | CASP7; MAPT; HSD17B10 |
hsa05033 | Nicotine addiction_Homo sapiens_hsa05033 | 3.192E-03 | 2.047E-02 | GRIA2; GRIA4 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 6.171E-03 | 2.880E-02 | FABP4; TSHR |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.387E-03 | 2.880E-02 | NFKB1; PPARD |
hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 5.143E-03 | 2.728E-02 | GRIA2; CASP1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 4.203E-03 | 2.411E-02 | CDA; CYP3A4 |
hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 7.055E-03 | 2.958E-02 | GRIA2; GRM1 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 6.387E-03 | 2.880E-02 | CASP1; NFKB1 |
hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 8.731E-03 | 3.282E-02 | GRIA2; GRIA4 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 8.236E-03 | 3.206E-02 | NFKB1; TLR2 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.606E-03 | 2.880E-02 | CYP1A2; CYP3A4 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.030E-02 | 3.454E-02 | NFKB1; TLR2 |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 9.499E-03 | 3.451E-02 | PPARA; NFKB1 |
hsa04742 | Taste transduction_Homo sapiens_hsa04742 | 1.316E-02 | 4.218E-02 | GRM4; GRM1 |
hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 7.993E-03 | 3.206E-02 | CASP1; NFKB1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.030E-02 | 3.454E-02 | CYP1A2; CYP3A4 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.470E-02 | 4.452E-02 | GRM5; GRM1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.408E-02 | 4.384E-02 | CASP1; NFKB1 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.046E-02 | 3.454E-02 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | GRM2 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | GRM2; GRM5 |
C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; CA9; NFKB1; TLR2 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | GRM2; GRM5; PPARD; MAPT |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | GRM1; GRM3; GRM2 |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Fragile X syndrome | F02.3, G20, Q99.2 | GRM5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | GRIK1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PPARD |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
NA: NA | Hepatitis C virus infection | NA | ADORA3 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | GRM3; GRM2; GRM2; GRM5; GRM5 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | GRIK1; GRM1 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | GRIA4; GRIA2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | GRM3; GRM2; GRM4; GRM5; CYP3A4 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GRM1; GRM3; GRM2; GRM5; MAPT |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
NA: NA | GERD | NA | GRM5 |
C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | GRM2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
G00-G99: Diseases of the nervous system G00-G99 | Chronic neuropathic pain | G64, G90.0, K21, R52, G89 | GRM5; GRM5 |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | GRIK1; GRM1; GRM5 |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | GRIK1; GRM1; GRM4; GRM5 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
NA: NA | Dyslipidemia | NA | PPARD |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | GRM1 |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | GRM5 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | GRIK1; GRIK1; CASP1 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; TLR2; CDA |
C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Autism | F84.0 | GRM5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |